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RoB 2: a revised tool for assessing risk of bias in  
randomised trials
Jonathan A C Sterne,1,2 Jelena Savović,1,3 Matthew J Page,4 Roy G Elbers,1 Natalie S Blencowe,1,2 
Isabelle Boutron,5,6,7 Christopher J Cates,8 Hung-Yuan Cheng,1,2 Mark S Corbett,9  
Sandra M Eldridge,10 Jonathan R Emberson,11 Miguel A Hernán,12 Sally Hopewell,13  
Asbjørn Hróbjartsson,14,15,16 Daniela R Junqueira,17 Peter Jüni,18 Jamie J Kirkham,19  
Toby Lasserson,20 Tianjing Li,21 Alexandra McAleenan,1 Barnaby C Reeves,2,22  
Sasha Shepperd,23 Ian Shrier,24 Lesley A Stewart,9 Kate Tilling,1,2,25 Ian R White,26  
Penny F Whiting,1,3 Julian P T Higgins1,2,3
Assessment of risk of bias is regarded 
as an essential component of a 
systematic review on the efects of an 
intervention. The most commonly used 
tool for randomised trials is the 
Cochrane risk-of-bias tool. We updated 
the tool to respond to developments in 
understanding how bias arises in 
randomised trials, and to address user 
feedback on and limitations of the 
original tool.
An evaluation of the risk of bias in each study included 
in a systematic review documents potential laws 
in the evidence summarised and contributes to the 
certainty in the overall evidence.1 The Cochrane tool 
for assessing risk of bias in randomised trials (RoB 
tool)2 has been widely used in both Cochrane and 
other systematic reviews, with over 40 000 citations in 
Google Scholar.
Many innovative characteristics of the original RoB 
tool have been widely accepted. It replaced the notion 
of assessing study quality with that of assessing risk 
of bias (we deine bias as a systematic deviation from 
the efect of intervention that would be observed in a 
large randomised trial without any laws). Quality is 
not well deined and can include study characteristics 
(such as performing a sample size calculation) that are 
not inherently related to bias in the study’s results. The 
RoB tool considers biases arising at diferent stages of 
a trial (known as bias domains), which were chosen on 
the basis of both empirical evidence and theoretical 
considerations. Assessments of risk of bias are 
supported by quotes from sources describing the trial 
(eg, trial protocol, registration record, results report) or 
by justiications written by the assessor.
After nearly a decade of experience of using the RoB 
tool, potential improvements have been identiied. 
A formal evaluation found some bias domains to 
be confusing at times, with assessment of bias due 
to incomplete outcome data and selective reporting 
of outcomes causing particular diiculties, and 
confusion over whether studies that were not blinded 
should automatically be considered to be at high 
risk of bias.3 More guidance on incorporating risk-
of-bias assessments into meta-analyses and review 
conclusions is also needed.4 5 A review of comments 
and user practice found that both Cochrane and non-
Cochrane systematic reviews often implemented the 
RoB tool in non-standard ways.6 Few trials are assessed 
as at low risk of bias, and judgments of unclear risk of 
bias are common.6 7 Empirical studies have found only 
moderate reliability of risk-of-bias judgments.8
We developed a revised risk-of-bias assessment 
tool to address these issues, incorporate advances 
in assessment of risk of bias used in other recently 
developed tools,9 10 and integrate recent developments 
in estimation of intervention efects from randomised 
trials.11
Development of the revised RoB tool
We followed the principles adopted for the development 
of the original RoB tool and for the ROBINS-I tool 
for assessing risk of bias in non-randomised stu-
dies of interventions.2 9 A core group coordinated 
development of the tool, including recruitment of 
collaborators, preparation and revision of documents, 
and administrative support.
Preliminary work included a review of how the 
original tool was used in practice,6 a systematic 
review and meta-analysis of meta-epidemiological 
studies of empirical evidence for biases associated 
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ɑ 3RWHQWLDOLPSURYHPHQWVWRWKH&RFKUDQHULVNRIELDVWRROZHUHLGHQWLЦHGRQ
WKHEDVLVRIUHYLHZVRIWKHOLWHUDWXUHXVHUH[SHULHQFHDQGIHHGEDFNDSSURDFKHV
XVHGLQRWKHUULVNRIELDVWRROVDQGUHFHQWGHYHORSPHQWVLQHVWLPDWLRQRI
LQWHUYHQWLRQHСHFWVIURPUDQGRPLVHGWULDOV
ɑ :HGHYHORSHGDQGSLORWHGDUHYLVHGWRROIRUDVVHVVLQJULVNRIELDVLQ
UDQGRPLVHGWULDOV5R%ʵ
ɑ %LDVLVDVVHVVHGLQЦYHGLVWLQFWGRPDLQV:LWKLQHDFKGRPDLQXVHUVRI5R%ʵ
DQVZHURQHRUPRUHVLJQDOOLQJTXHVWLRQV7KHVHDQVZHUVOHDGWRMXGJPHQWVRI
ɌORZULVNRIELDVɍɌVRPHFRQFHUQVɍRUɌKLJKULVNRIELDVɍ
ɑ 7KHMXGJPHQWVZLWKLQHDFKGRPDLQOHDGWRDQRYHUDOOULVNRIELDVMXGJPHQWIRU
WKHUHVXOWEHLQJDVVHVVHGZKLFKVKRXOGHQDEOHXVHUVRI5R%ʵWRVWUDWLI\PHWD
DQDO\VHVDFFRUGLQJWRULVNRIELDV
 o
n
 6 Septem
ber 2019 at The Librarian J B M
orrell Library. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.l4898 on 28 August 2019. Downloaded from 
ReseaRch Methods and RepoRting
2 doi: 10.1136/bmj.l4898 | BMJ 2019;366:l4898 | the bmj
with characteristics of randomised trials,12 and a cross 
sectional study of how selective outcome reporting 
was assessed in Cochrane reviews.13 We also drew on 
a systematic review of the theoretical and conceptual 
literature on types of bias in epidemiology, which 
sought papers and textbooks presenting classiications 
or deinitions of biases, and organised these into a 
coherent framework (paper in preparation).
The core group developed an initial proposal 
and presented it, together with the latest empirical 
evidence of biases in randomised trials, at a meeting 
in August 2015 attended by 24 contributors. Meeting 
participants agreed on the methodological principles 
underpinning the new tool and the bias domains to 
be addressed, and formed working groups for each 
domain. The groups were tasked with developing 
signalling questions (reasonably factual questions with 
yes/no answers that inform risk-of-bias judgments), 
together with guidance for answering these questions 
and broad considerations for how to judge the risk of 
bias for the domain.
The materials prepared by the working groups 
were assembled and edited by the core team, and 
the resulting draft was piloted by experienced and 
novice systematic reviewers during a three day event 
in February 2016, with 17 participants present and 10 
participants contributing remotely. Issues identiied in 
the pilot were recorded and addressed in a new draft 
discussed at a second development meeting in April 
2016, also attended by 24 contributors. Subsequently, 
working groups developed criteria for reaching 
domain level, risk-of-bias judgments based on answers 
to signalling questions, and expanded the guidance. 
The core team designed algorithms to match the 
criteria, which were checked by the working groups. 
The resulting revision was tested in another round of 
piloting by 10 systematic review authors in mid-2016.
A complete draft of version 2 of the RoB tool (RoB 
2), together with detailed guidance, was posted at 
www.riskofbias.info in October 2016, coinciding 
with the Cochrane Colloquium in Seoul, South Korea. 
Feedback was invited through direct contact with the 
development group. Several review teams subsequently 
piloted the draft tool and provided feedback. Further 
modiications—particularly improvements in wording 
and clarity, splitting compound signalling questions, 
adding new questions, and addressing methodological 
issues—were made on the basis of feedback from 
training events (including webinars) conducted 
between 2016 and 2019, as well as individual feedback 
from users worldwide.
Version 2 of the Cochrane tool for assessing risk of bias 
in randomised trials (RoB 2)
RoB 2 provides a framework for assessing the risk 
of bias in a single estimate of an intervention efect 
reported from a randomised trial. The efect assessed 
is a comparison of two interventions, which we refer 
to as the experimental and comparator interventions, 
for a speciic outcome or endpoint. The process of 
making a RoB 2 assessment is summarised in igure 1. 
Preliminary considerations (box 1) include specifying 
which result is being assessed, specifying how this 
result is being interpreted (see “The intervention 
efect of interest” below), and listing the sources of 
information used to inform the assessment. Review 
authors should contact trial authors in order to obtain 
information that is omitted from published and online 
sources, so far as this is feasible. Note that risk-of-bias 
assessments might be needed for results relating to 
multiple outcomes from the included trials.
RoB 2 is structured into ive bias domains, listed 
in table 1. The domains were selected to address 
all important mechanisms by which bias can be 
introduced into the results of a trial, based on a 
combination of empirical evidence and theoretical 
considerations. We did not include domains for 
features that would be expected to operate indirectly, 
through the included bias domains.14 15 For this 
reason, we excluded some trial features, such as 
funding source and single centre versus multicentre 
status, which have been associated empirically with 
trial efect estimates from trials.
We label the domains using descriptions of the 
causes of bias addressed, avoiding terms used 
in the original RoB tool (such as “selection bias” 
and “performance bias”) because they are used 
inconsistently or not known by many people outside 
Cochrane.16 Each domain is mandatory, and no 
others can be added, although we have developed 
versions of RoB 2 that deal with additional issues that 
arise in trials with cluster randomised or crossover 
designs (www.riskofbias.info). Within each domain, 
the assessment comprises:
For each outcome
1. Specify result being assessed
2. Specify effect of interest
3. List sources of information used to inform assessment
4. Answer signalling questions
5. Judge risk of bias for each domain
6. Judge overall risk of bias for the result
For each study
Risk of bias assessment for a specific result
Eg, stratify meta-analysis by overall risk-of-bias judgment
For the synthesis
Integrate judgment(s) into results and conclusions
Fig 1 | Summary of the process of assessing risk of bias in a systematic review of 
randomised trials, using version 2 of the Cochrane risk-of-bias tool
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Ŷ A series of signalling questions
Ŷ A judgment about risk of bias for the domain, 
facilitated by an algorithm that maps responses to 
signalling questions to a proposed judgment
Ŷ Free text boxes to justify responses to the 
signalling questions and risk-of-bias judgments
Ŷ Optional free text boxes to predict (and explain) 
the likely direction of bias.
Table 2 lists the most important changes made in 
RoB 2, compared with the original Cochrane RoB tool.
Signalling questions
Signalling questions aim to elicit information relevant 
to an assessment of risk of bias (table 1). The questions 
seek to be reasonably factual in nature. The response 
options are “yes,” “probably yes,” “probably no,” “no,” 
and “no information.” To maximise their simplicity 
and clarity, signalling questions are phrased such 
that a yes answer might indicate either lower or higher 
risk of bias, depending on the most natural way to 
ask the question. The online supplementary material 
in the web appendix includes elaborations providing 
guidance on how to answer each question.
Responses of “yes” and “probably yes” have the 
same implications for risk of bias, as do responses 
of “no” and “probably no.” “Yes” and “no” typically 
imply that irm evidence is available; the “probably” 
responses typically imply that a judgment has been 
made. Where there is a need to distinguish between 
“some concerns” and “high risk of bias,” this is dealt 
with by using an additional signalling question, rather 
than by making a distinction between responses 
“probably yes” and “yes,” or between “probably no” 
and “no.” The “no information” response should be 
used only when insuicient details are available to 
allow a diferent response, and when, in the absence 
of these details, it would be unreasonable to respond 
“probably yes” or “probably no.” For example, in 
the context of a large trial run by an experienced 
clinical trials unit, absence of speciic information 
about generation of the randomisation sequence, in a 
paper published in a journal with rigorously enforced 
word count limits, is likely to result in a response of 
“probably yes” rather than “no information” to the 
signalling question about sequence generation (the 
rationale for the response should be provided in the 
free text box). Some signalling questions are answered 
only if the response to a previous question indicates 
that they are required.
The intervention efect of interest
Assessments for the domain “bias due to deviations 
from intended interventions” difer according to 
whether review authors are interested in quantifying 
the efect of assignment to the interventions at baseline 
regardless of whether the interventions are received 
during follow-up (intention-to-treat efect), or the 
efect of adhering to intervention as speciied in the 
trial protocol (per protocol efect). These efects will 
difer if some patients do not receive their assigned 
intervention or deviate from the assigned intervention 
after baseline. Each efect might be of interest.11 For 
example, the efect of assignment to intervention 
might be appropriate to inform a health policy 
question about whether to recommend an intervention 
(eg, a screening programme) in a particular health 
system, whereas the efect of adhering to intervention 
more directly informs a care decision by an individual 
patient (eg, whether to be screened). Changes to an 
intervention that are consistent with the trial protocol 
(even if not explicitly discussed in the protocol), such 
as cessation of a drug because of toxicity or switch to 
second line chemotherapy because of progression of 
cancer, do not cause bias and should not be considered 
to be deviations from intended intervention.
The efect of assignment to intervention should be 
estimated by an intention-to-treat analysis that includes 
all randomised participants.17 However, estimates 
of per protocol efects commonly used in reports 
of randomised trials are problematic and might be 
seriously biased.18 These estimates include those from 
naive per protocol analyses restricted to individuals 
who adhered to their assigned intervention, and as-
treated analyses in which participants are analysed 
according to the intervention they received, even if 
their assigned group is diferent. These approaches 
are problematic because prognostic factors could 
Box 1: RoB 2 tool: preliminary considerations
ɑ)RUWKHSXUSRVHVRIWKLVDVVHVVPHQWGHILQHWKHLQWHUYHQWLRQVEHLQJFRPSDUHG
 ƕ ([SHULPHQWDOLQWHUYHQWLRQ
 ƕ &RPSDUDWRULQWHUYHQWLRQ
ɑ6SHFLI\ZKLFKRXWFRPHLVEHLQJDVVHVVHGIRUULVNRIELDV
ɑ6SHFLI\WKHQXPHULFDOUHVXOWEHLQJDVVHVVHG,QFDVHRIPXOWLSOHDOWHUQDWLYHDQDO\VHV
EHLQJSUHVHQWHGVSHFLI\WKHQXPHULFDOUHVXOWHJULVNUDWLRʴ ʸʵʼʸFRQILGHQFH
LQWHUYDOʳ ʻʶWRʵ ʺʺRUDUHIHUHQFHHJWRDWDEOHILJXUHRUSDUDJUDSKWKDWXQLTXHO\
GHILQHVWKHUHVXOWEHLQJDVVHVVHG
ɑ,VWKHUHYLHZWHDPɊVDLPIRUWKLVUHVXOWFKHFNRQH
 ƕ 7RDVVHVVWKHHIIHFWRIDVVLJQPHQWWRLQWHUYHQWLRQWKHLQWHQWLRQWRWUHDWHIIHFW"
 ƕ 7RDVVHVVWKHHIIHFWRIDGKHULQJWRLQWHUYHQWLRQWKHSHUSURWRFROHIIHFW"
ɑ,IWKHDLPLVWRDVVHVVWKHHIIHFWRIDGKHULQJWRLQWHUYHQWLRQVHOHFWWKHGHYLDWLRQVIURP
LQWHQGHGLQWHUYHQWLRQWKDWVKRXOGEHDGGUHVVHGDWOHDVWRQHPXVWEHFKHFNHG
 ƕ 2FFXUUHQFHRIQRQSURWRFROLQWHUYHQWLRQV
 ƕ )DLOXUHVLQLPSOHPHQWLQJWKHLQWHUYHQWLRQWKDWFRXOGKDYHDIIHFWHGWKHRXWFRPH
 ƕ 1RQDGKHUHQFHWRWKHLUDVVLJQHGLQWHUYHQWLRQE\WULDOSDUWLFLSDQWV
ɑ:KLFKRIWKHIROORZLQJVRXUFHVZHUHREWDLQHGWRKHOSLQIRUPWKHULVNRIELDV
DVVHVVPHQW"
 ƕ -RXUQDODUWLFOHV
 ƕ 7ULDOSURWRFRO
 ƕ 6WDWLVWLFDODQDO\VLVSODQ
 ƕ 1RQFRPPHUFLDOWULDOUHJLVWU\UHFRUGHJ&OLQLFDO7ULDOVJRYUHFRUG
 ƕ &RPSDQ\RZQHGWULDOUHJLVWU\UHFRUGHJ*OD[R6PLWK.OLQH&OLQLFDO6WXG\ 
5HJLVWHUUHFRUG
 ƕ *UH\OLWHUDWXUHHJXQSXEOLVKHGWKHVLV
 ƕ &RQIHUHQFHDEVWUDFWVDERXWWKHWULDO
 ƕ 5HJXODWRU\GRFXPHQWHJFOLQLFDOVWXG\UHSRUWGUXJDSSURYDOSDFNDJH
 ƕ 5HVHDUFKHWKLFVDSSOLFDWLRQ
 ƕ *UDQWGDWDEDVHVXPPDU\HJ1,+5H3257(5RU5HVHDUFK&RXQFLOV8. 
*DWHZD\WR5HVHDUFK
 ƕ 3HUVRQDOFRPPXQLFDWLRQZLWKWULDOOLVW
 ƕ 3HUVRQDOFRPPXQLFDWLRQZLWKWKHVSRQVRU
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inluence whether individuals receive their allocated 
intervention. Data from a randomised trial can be used 
to derive an unbiased estimate of the efect of adhering 
to intervention.19 20 However, the validity of appropriate 
methods depends on strong assumptions, and 
published applications are relatively rare to date. For 
trials comparing interventions that are sustained over 
time, appropriate methods also require measurement 
of and adjustment for the values of prognostic factors, 
both before and after randomisation, that predict 
Table 1 | Version 2 of the Cochrane risk-of-bias assessment tool for randomised trials: bias domains, signalling 
questions, response options, and risk-of-bias judgments
Bias domain and signalling question*
Response options
Lower risk of bias Higher risk of bias Other
Bias arising from the randomisation process
1.1 Was the allocation sequence random? Y/PY N/PN NI
1.2 Was the allocation sequence concealed until participants were enrolled and 
assigned to interventions?
Y/PY N/PN NI
1.3 Did baseline diferences between intervention groups suggest a problem with the 
randomisation process?
N/PN Y/PY NI
Risk-of-bias judgment (low/high/some concerns)
Optional: What is the predicted direction of bias arising from the randomisation 
process?
Bias due to deviations from intended interventions
2.1 Were participants aware of their assigned intervention during the trial? N/PN Y/PY NI
2.2 Were carers and people delivering the interventions aware of participants’  
assigned intervention during the trial?
N/PN Y/PY NI
2.3 If Y/PY/NI to 2.1 or 2.2: Were there deviations from the intended intervention that 
arose because of the trial context?
N/PN Y/PY NA/NI
2.4 If Y/PY/NI to 2.3: Were these deviations likely to have afected the outcome? N/PN Y/PY NA/NI
2.5 If Y/PY to 2.4: Were these deviations from intended intervention balanced  
between groups?
Y/PY N/PN NA/NI
2.6 Was an appropriate analysis used to estimate the efect of assignment to  
intervention?
Y/PY N/PN NI
2.7 If N/PN/NI to 2.6: Was there potential for a substantial impact (on the result) of the 
failure to analyse participants in the group to which they were randomised?
N/PN Y/PY NA/NI
Risk-of-bias judgment (low/high/some concerns)
Optional: What is the predicted direction of bias due to deviations from intended 
interventions?
Bias due to missing outcome data
3.1 Were data for this outcome available for all, or nearly all, participants randomised? Y/PY N/PN NI
3.2 If N/PN/NI to 3.1: Is there evidence that the result was not biased by missing 
outcome data?
Y/PY N/PN NA
3.3 If N/PN to 3.2: Could missingness in the outcome depend on its true value? N/PN Y/PY NA/NI
3.4 If Y/PY/NI to 3.3: Is it likely that missingness in the outcome depended on its true 
value?
N/PN Y/PY NA/NI
Risk-of-bias judgment (low/high/some concerns)
Optional: What is the predicted direction of bias due to missing outcome data?
Bias in measurement of the outcome
4.1 Was the method of measuring the outcome inappropriate? N/PN Y/PY NI
4.2 Could measurement or ascertainment of the outcome have difered between  
intervention groups?
N/PN Y/PY NI
4.3 If N/PN/NI to 4.1 and 4.2: Were outcome assessors aware of the intervention 
received by study participants?
N/PN Y/PY NI
4.4 If Y/PY/NI to 4.3: Could assessment of the outcome have been influenced by  
knowledge of intervention received?
N/PN Y/PY NA/NI
4.5 If Y/PY/NI to 4.4: Is it likely that assessment of the outcome was influenced by 
knowledge of intervention received?
N/PN Y/PY NA/NI
Risk-of-bias judgment (low/high/some concerns)
Optional: What is the predicted direction of bias in measurement of the outcome?
Bias in selection of the reported result
5.1 Were the data that produced this result analysed in accordance with a prespeciied 
analysis plan that was inalised before unblinded outcome data were available for 
analysis?
Y/PY N/PN NI
Is the numerical result being assessed likely to have been selected, on the basis of the results, from: 
  5.2 ... multiple eligible outcome measurements (eg, scales, deinitions, time points) 
within the outcome domain?
N/PN Y/PY NI
 5.3 ... multiple eligible analyses of the data? N/PN Y/PY NI
Risk-of-bias judgment (low/high/some concerns)
Optional: What is the predicted direction bias due to selection of the reported results?
Overall bias
Risk-of-bias judgment (low/high/some concerns)
Optional: What is the overall predicted direction of bias for this outcome?
Y=yes; PY=probably yes; PN=probably no; N=no; NA=not applicable; NI=no information.
*Signalling questions for bias due to deviations from intended interventions relate to the efect of assignment to intervention.
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deviations from intervention.11 For these reasons, most 
systematic reviews are likely to estimate the efect of 
assignment rather than adherence to intervention.
Risk-of-bias judgments
The risk-of-bias judgments for each domain are “low 
risk of bias,” “some concerns,” or “high risk of bias.” 
Judgments are based on, and summarise, the answers 
to signalling questions. Review authors should 
interpret “risk of bias” as “risk of material bias”: 
concerns should be expressed only about issues likely 
to have a notable efect on the result being assessed.
An important innovation in RoB 2 is the inclusion 
of algorithms that map responses to signalling 
questions to a proposed risk-of-bias judgment for 
each domain (see online supplementary material in 
the web appendix). Review authors can override these 
proposed judgments if they feel it is appropriate to 
do so.
Free text boxes alongside the signalling questions 
and judgments allow assessors to provide support for 
the responses. Brief direct quotations from the texts 
of the study reports (including trial protocols) should 
be used whenever possible, supplemented by any 
information obtained from authors when contacted. 
Reasons for any judgments that do not follow the 
algorithms should be provided. RoB 2 includes 
optional judgments of the direction of the bias for each 
domain and overall. If review authors do not have a 
clear rationale for judging the likely direction of the 
bias, they should not guess it.
Overall risk of bias for the result
The response options for an overall risk-of-bias 
judgment are the same as for individual domains. Table 
3 shows the approach to mapping bias judgments 
within domains to an overall judgment for the result. 
The overall risk of bias generally corresponds to the 
worst risk of bias in any of the domains. However, if 
a study is judged to have “some concerns” about risk 
of bias for multiple domains, it might be judged as at 
high risk of bias overall. Figure 2 shows a forest plot 
that displays domain speciic risk of bias and overall 
risk of bias, with the meta-analysis stratiied by overall 
risk of bias.
Discussion
We have substantially revised the Cochrane tool for 
assessing risk of bias in the results of randomised trials, 
in order to address limitations identiied since it was 
published in 2008 and to incorporate improvements 
that aim to increase the reliability of assessments. 
Table 2 | Major changes in version 2 of the Cochrane risk-of-bias assessment tool, compared with the original tool
Bias domain Major changes compared with original risk-of-bias tool
Bias arising from the 
randomisation process
The original tool did not deal with issues relating to baseline diferences. We emphasise that baseline diferences 
that are compatible with chance do not lead to a risk of bias.
Bias due to deviations 
from intended inter-
ventions
1. The original tool only dealt with whether participants, carers, and people delivering the interventions were 
aware of participants’ assigned intervention during the trial. The revised tool recognises that open trials can be at 
low risk of bias, if there were no deviations from intended intervention that arose because of the trial context.
2. Whether the analysis was appropriate to estimate the efect of assignment to intervention was previously 
assessed in relation to missing outcome data.
3. The original tool did not address bias in estimating the efect of adhering to intervention. Imbalances in 
co-interventions, failures in implementing the intervention, and non-adherences can all bias such estimates. An 
appropriate analysis has the potential to deal with such biases, in some circumstances.
Bias due to missing 
outcome data
1. Issues relating to exclusions in analyses (eg, naive per protocol analyses) are now dealt with in the “deviations 
from intended intervention” domain.
2. Whether missing outcome data lead to bias depends on the relation between the true value of the outcome in 
participants with missing outcome data, and the missingness mechanism (that is, the process that led to outcome 
data being missing). This domain has been substantially reworked, to reflect situations in which missing outcome 
data do and do not lead to bias in a complete case analysis.
3. We clarify that multiple imputation methods will not remove or reduce bias that occurs when missingness in the 
outcome depends on its true value, unless such missingness can be explained by measured variables.
Bias in measurement of 
the outcome
The original tool only dealt with whether outcome assessors were aware of the intervention received by study 
participants. This domain now covers a range of ways in which the method of outcome measurement can lead 
to bias, including issues related to passive detection of outcomes that might be particularly relevant for adverse 
efects (harms) of interventions.
Bias in selection of the 
reported result
1. Unlike the original tool, this domain does not deal with bias due to selective non-reporting of results (either 
because of non-publication of whole studies or selective reporting of outcomes) for outcome domains that were 
measured and analysed. Such bias puts the result of a synthesis at risk because results are omitted based on their 
direction, magnitude, or statistical signiicance. It should therefore be dealt with at the review level, as part of an 
integrated assessment of the risk of reporting bias.
2. A judgment of low risk of bias requires that the trial was analysed in accordance with a prespeciied plan that 
was inalised before unblinded outcome data were available for analysis.
Table 3 | Approach to reaching an overall risk-of-bias judgment for a speciic result
Overall risk-of-bias judgment Criteria
Low risk of bias The study is judged to be at low risk of bias for all domains for this result
Some concerns The study is judged to raise some concerns in at least one domain for this result, but not to be at high 
risk of bias for any domain
High risk of bias The study is judged to be at high risk of bias in at least one domain for this result, or the study is judged 
to have some concerns for multiple domains in a way that substantially lowers conidence in the result
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RoB 2 is based on wide consultation within and 
outside Cochrane, extensive piloting, and integration 
of feedback based on user experience. Assessments 
are made in ive bias domains, within which answers 
to signalling questions address a broader range of 
issues than in the original RoB tool. These issues 
include whether post-randomisation deviations from 
intervention caused bias in trials in which blinding was 
either not feasible or not implemented and whether 
outcome data were missing for reasons likely to lead 
to bias. Assessment of selective reporting is focused on 
a reported result for an outcome, rather than selective 
non-reporting of other outcomes that were measured in 
the trial. RoB 2 also incorporates recent developments 
in estimation of intervention efects from randomised 
trials: we distinguish bias in the efect of assignment 
to interventions from bias in the efect of adhering to 
intervention as speciied in the trial protocol.11
RoB 2 assessments relate to the risk of bias in a 
single estimate of intervention efect for a single 
outcome or endpoint, rather than for a whole trial. 
This speciicity is because the risk of bias is outcome 
speciic for domains such as bias in measurement of the 
outcome, and could be speciic to a particular estimate 
(eg, when both intention-to-treat and per protocol 
analyses have been conducted). We recommend that 
overall RoB 2 judgments of risk of bias for individual 
results should be the primary means of distinguishing 
Low risk of bias
  Šerifović 2007
  Loreen 2012
  Jamala 2016
Subtotal
Test for heterogeneity: τ2=0.22; χ2=9.60, df=2, P=0.008; I2=79%
Test for overall eﬀect: Z=2.79, P=0.005
Some concerns
  Ruslana 2004
  Zelmerlöw 2015a
  Zelmerlöw 2015b
  Wurst 2014
  de Forest 2013
  Bilan 2008
  Erener 2003
Subtotal
Test for heterogeneity: τ2=0.05; χ2=13.59, df=6, P=0.03; I2=56%
Test for overall eﬀect: Z=2.59, P=0.01
High risk of bias
  Rybak 2009
  Netta 2018
  Lena 2010
  Salvador 2017
  Sobral 2017
Subtotal
Test for heterogeneity: τ2=0.61; χ2=36.05, df=4, P<0.001; I2=89%
Test for overall eﬀect: Z=2.96, P=0.003
Total (95% CI)
Test for heterogeneity: τ2=0.18; χ2=71.47, df=14, P<0.001; I2=80%
Test for overall eﬀect: Z=5.14, P<0.001
Test for subgroup diﬀerences: χ2=5.55, df=2, P=0.06; I2=64%
1.33 (0.79 to 1.87)
0.91 (0.25 to 1.57)
0.43 (0.18 to 0.68)
0.85 (0.25 to 1.45)
0.05 (-0.96 to 1.06)
0.21 (-0.03 to 0.45)
0.19 (-0.57 to 0.95)
1.26 (0.63 to 1.89)
0.45 (0.27 to 0.63)
-0.09 (-0.70 to 0.52)
0.13 (-0.43 to 0.69)
0.33 (0.08 to 0.59)
0.72 (0.23 to 1.21)
1.24 (0.56 to 1.92)
0.07 (-0.30 to 0.44)
1.60 (0.97 to 2.23)
2.06 (1.38 to 2.74)
1.11 (0.37 to 1.84)
0.68 (0.42 to 0.93)
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Fig 2 | Example forest plot showing results of a risk-of-bias assessment in a systematic review of randomised trials, using version 2 of the Cochrane 
risk-of-bias tool. Studies are stratiied by overall risk of bias
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stronger from weaker evidence in the context of a meta-
analysis (or other synthesis) of randomised trials. The 
overall judgments should also inluence the strength 
of conclusions drawn from a systematic review 
(potentially as part of a GRADE assessment).21 We 
strongly encourage stratiication by overall risk-of-bias 
judgment as a default meta-analysis strategy, as shown 
in igure 2. To facilitate this, we suggest that software 
for systematic review preparation provides data ields 
for risk-of-bias assessments. We are preparing an 
interactive web tool for completing RoB 2 assessments, 
which we hope will interface well with other systematic 
review software.
In RoB 2, judgments about risk of bias are derived by 
algorithms on the basis of answers to speciic signalling 
questions. The added structure provided by the signa-
lling questions aims to make the assessment easier and 
more eicient to use, as well as to improve agreement 
between assessors. We believe this approach to be more 
straightforward than the direct judgments about risk of 
bias required in the original RoB tool. The algorithms 
include explicit mappings for situations where there is 
no information to answer a signalling question, which 
do not necessarily map to a negative assessment of 
the trial. For example, when randomisation methods 
are described and are adequate, the response to 
the signalling question about baseline imbalances 
between intervention groups leads to low risk of 
bias either when such imbalances are compatible 
with chance, or when there is no information about 
baseline imbalances. We removed the option of 
an “unclear” judgment in favour of a graded set of 
response options (from “low” to “some concerns” 
to “high”). We envisage that systematic reviews will 
report the domain level judgments and overall risk-
of-bias judgments in tables or igures contained in the 
main review text. In addition, we encourage reporting 
of answers to signalling questions, together with direct 
quotes from papers and free text justiication of the 
answers, in an appendix.
We expect the reinements we have made to the 
RoB tool to lead to a greater proportion of trial results 
being assessed as at low risk of bias, because our 
algorithms map some circumstances to a low risk of 
bias when users of the previous tool would typically 
have assessed them to be at unclear (or even high) 
risk of bias. This potential diference in judgments in 
RoB 2 compared with the original tool is particularly 
the case for unblinded trials, where risk of bias in the 
efect of assignment to intervention due to deviations 
from intended interventions might be low despite 
many users of the original RoB tool assigning a high 
risk of bias in the corresponding domain. We believe 
that judgments of low risk of bias should be readily 
achievable for a randomised trial, a study design that 
is scientiically strong, well understood, and often well 
implemented in practice. We hope that RoB 2 will be 
useful to systematic review authors and those making 
use of reviews, by providing a coherent framework for 
understanding and identifying trials at risk of bias. 
This framework might also help those designing, 
conducting, and reporting randomised trials to achieve 
the most reliable indings possible.
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